Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

W. Armstrong, Paul; Pieske, Burkert; J. Anstrom, Kevin; A. Ezekowitz, Justin; F. Hernandez, Adrian; Butler, Javed; S.P. Lam, Carolyn; Ponikowski, Piotr; A. Voors, Adriaan; Jia, Gang; E. McNulty, Steven; J. Patel, Mahesh; Roessig, Lothar; Koglin, Joerg; M. O’Connor, Christopher

doi:10.1056/nejmoa1915928

Public

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Published in New England Journal of Medicine • Mar 28, 2020

Authors:

Paul W. Armstrong

Burkert Pieske

Kevin J. Anstrom

Abstract

BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placeb...

Subject

Ejection fraction

Heart failure

Cardiology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!